<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03017872</url>
  </required_header>
  <id_info>
    <org_study_id>D2EFT</org_study_id>
    <secondary_id>18Q065</secondary_id>
    <nct_id>NCT03017872</nct_id>
  </id_info>
  <brief_title>Dolutegravir and Darunavir Evaluation in Adults Failing Therapy</brief_title>
  <acronym>D²EFT</acronym>
  <official_title>A Phase IIIB/IV Randomised Open-label Trial Comparing Dolutegravir With Pharmaco-enhanced Darunavir Versus Dolutegravir With Predetermined Nucleosides Versus Recommended Standard of Care ART Regimens in Patients With HIV-1 Infection Failing First Line Therapy.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kirby Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>UNITAID</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Health and Medical Research Council, Australia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>ViiV Healthcare</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Janssen Pharmaceutica</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Kirby Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      D²EFT is a randomised, open-label study in HIV-1 infected patients failing first-line
      antiretroviral therapy (ART). The study compares 2 regimens of second-line ART (dolutegravir
      and darunavir pharmaco-enhanced with ritonavir and dolutegravir and 2 prespecified NRTIs)
      with the WHO recommended regimen of 2NRTIs plus a ritonavir-boosted PI (Standard of Care
      (SOC)). 1,010 participants from 14 predominantly low-middle income countries will be followed
      for 96 weeks with the primary endpoint at week 48. The design is based on the hypothesis that
      one or both of the new regimens will be non-inferior to SOC in terms of virologic control
      while being easier to take, economically viable and affording simplification of treatment
      programs.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Consenting participants will be screened and within 45 days randomly allocated to receive
      either dolutegravir and darunavir/ritonavir, dolutegravir and 2 prespecified NRTIs or the SOC
      regimen. Participants will be seen four weeks after their randomisation (week 0) visit and
      then at weeks 12, 24, 48 and 96. Consenting participants will have storage samples collected
      and cryopreserved at their week 0, 48 &amp; 96 visits. This repository will be used in future for
      central baseline resistance testing, pharmacogenomic testing (separate consent required) and
      has inherent value for later studies of HIV pathogenesis. A 1-time PK sample will be
      collected at week four for future testing and any participants failing therapy at 24 weeks
      will have a plasma sample stored for future genotypic resistance testing.

      A number of secondary outcomes will be considered in order to compare the performance of the
      two study treatment regimens. Secondary analyses will focus on virological, immunological,
      safety, antiretroviral treatment change and medication adherence. A comparison of costs and
      estimates of cost-effectiveness for the randomised comparison will be a critical component of
      this study. ART costs will be assessed across study arms. Health-care utilisation will be
      self-reported and then used to estimate costs. Safety data, viral loads and quality of life
      data will also be analysed.

      The open label nature of the study allows routine care to be undertaken and the use of
      objective endpoints limit potential bias. The study has well defined and integrated clinical
      data collection and patient management systems that have been shown to be effective in a wide
      range of clinical settings.

      The choice of NRTIs in the SoC regimen is based on clinical judgement and may be guided by
      resistance testing if locally available, while those used with dolutegravir are predetermined
      (tenofovir and lamivudine or emtricitabine). The NRTIs are not provided via the study. At the
      end of 96 weeks (completion of the protocol) study drug can be offered to all participants
      for a further 48 weeks as informed by the 48-week study results and clinical judgement. After
      144 weeks study drug will no longer be available and composition of the participant's
      post-study regimen will be the clinician's decision.'
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 23, 2017</start_date>
  <completion_date type="Anticipated">December 28, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>A third arm has been incorporated using a multi-arm, multi-stage (MAMS) design. This design allows for the 2-arm study (DTG+DRV/r vs DRV/r+2NRTI) to continue accrual while preparation of the new arm (DTG+2NRTI) is begun in parallel. Once that arm is ready, accrual to it begins and the study switches to the second stage. All participants accrued to Arm 1 and 2 throughout the trial are contemporaneous and can be compared, while the subjects accrued to Arm 3 are compared only to their contemporaries in Arms 1 and 2. The size of Arm 3 is sufficient to allow adequate power comparisons, and stage effects are minimized while non-contemporaneous control data are not required.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The proportion of participants in each arm whose plasma viral load is &lt;50 copies/mL at 48 weeks by intention to treat.</measure>
    <time_frame>At 48 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion with plasma viral load &lt;200 copies/mL</measure>
    <time_frame>At 48 and 96 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion with plasma viral load &lt;50 copies/mL where those stopping randomised therapy for any reason are classified as plasma viral load &gt;50 copies/mL</measure>
    <time_frame>At 48 and 96 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change in CD4+ cell count from baseline</measure>
    <time_frame>At 48 and 96 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean/median changes from baseline in fasted lipids (Total cholesterol, LDL-c, HDL-c, and triglycerides)</measure>
    <time_frame>At 48 and 96 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total number of participants with any serious adverse events (SAEs), and the cumulative incidence of SAEs</measure>
    <time_frame>At 48 and 96 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total number of opportunistic diseases (AIDS events), deaths and serious non-AIDS defining events and the cumulative incidence of these</measure>
    <time_frame>At 48 and 96 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events associated with cessation of randomly assigned therapy</measure>
    <time_frame>At 48 and 96 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Categorisation of neuropsychological adverse events</measure>
    <time_frame>At 48 and 96 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion who stopped randomised therapy by reason for stopping</measure>
    <time_frame>At 48 and 96 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patterns of genotypic HIV resistance associated with virological failure</measure>
    <time_frame>At 48 and 96 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adherence assessment using participant 7-day recall self-report questionnaire</measure>
    <time_frame>At week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life and anxiety &amp; depression assessed by participant questionnaire</measure>
    <time_frame>At 48 and 96 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health care utilisation assessed by participant questionnaire</measure>
    <time_frame>At 48 and 96 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost of care assessment</measure>
    <time_frame>At 48 and 96 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">1010</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>Standard of Care (SoC) arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2 x NRTIs + darunavir/ritonavir 800mg/100mg po od</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dolutegravir arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dolutegravir 50mg + darunavir/ritonavir 800mg/100mg po od</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dolutegravir 2NRTI arm (D2N)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dolutegravir 50mg + 2 x NRTIs (tenofovir plus emtricitabine or lamivudine)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NRTIs</intervention_name>
    <description>In SOC arm, choice of NRTIs determined by clinician, guided by either genotypic resistance testing or use of a protocol-specified algorithm for N(t)RTI selection.
In D2N arm, NRTIs are predetermined.</description>
    <arm_group_label>Dolutegravir 2NRTI arm (D2N)</arm_group_label>
    <arm_group_label>Standard of Care (SoC) arm</arm_group_label>
    <other_name>Nucleoside/Nucleotide Reverse Transcription Inhibitors</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dolutegravir</intervention_name>
    <description>50mg tablet by mouth once daily for 96 weeks.</description>
    <arm_group_label>Dolutegravir 2NRTI arm (D2N)</arm_group_label>
    <arm_group_label>Dolutegravir arm</arm_group_label>
    <other_name>Tivicay</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Darunavir</intervention_name>
    <description>800mg tablet by mouth once daily for 96 weeks.</description>
    <arm_group_label>Dolutegravir arm</arm_group_label>
    <arm_group_label>Standard of Care (SoC) arm</arm_group_label>
    <other_name>Prezista</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ritonavir</intervention_name>
    <description>100mg tablet by mouth once daily for 96 weeks.</description>
    <arm_group_label>Dolutegravir arm</arm_group_label>
    <arm_group_label>Standard of Care (SoC) arm</arm_group_label>
    <other_name>Norvir</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. HIV-1 positive by licensed diagnostic test

          2. Aged ≥16 years of age (or minimum age as determined by local regulations or as legal
             requirements dictate)

          3. Failed first-line non-nucleoside reverse transcriptase inhibitor (NNRTI) + 2N(t)RTI
             combination therapy according to virological criteria, defined as at least two
             consecutive (≥7 days apart) pVL results &gt;500 copies/mL after a minimum period of
             exposure to continuous NNRTI + 2N(t)RTI first-line therapy of 24 weeks (only the
             second pVL result needs to be within 45 days of randomisation)

          4. For women of child-bearing potential, willingness to use appropriate contraception

          5. Able to provide written informed consent

        Exclusion Criteria:

          1. The following laboratory variables:

               1. absolute neutrophil count (ANC) &lt;500 cells/µL

               2. haemoglobin &lt;7.0 g/dL

               3. platelet count &lt;50,000 cells/µL

               4. AST and/or ALT ≥5xULN OR ALT ≥3xULN and bilirubin ≥1.5xULN (with &gt;35% direct
                  bilirubin)

          2. Change in antiretroviral therapy within 12 weeks prior to randomisation

          3. Prior exposure to HIV protease inhibitors and/or HIV integrase inhibitors

          4. Patients with chronic viral hepatitis B infection defined by positive serum hepatitis
             B surface antigen

          5. Unstable liver disease (as defined by the presence of ascites, encephalopathy,
             coagulopathy (INR &gt;2.3), hypoalbuminemia (serum albumin &lt;2.8g/dL), esophageal or
             gastric varices, or persistent jaundice), known biliary abnormalities (with the
             exception of Gilbert's syndrome or asymptomatic gallstones)

          6. Anticipated need for Hepatitis C virus (HCV) therapy during the study

          7. Subject has creatinine clearance of &lt;50 mL/min via CKD-EPI equation

          8. Current use of rifabutin or rifampicin

          9. Use of any contraindicated medications (as specified by product information sheets)

         10. Intercurrent illness requiring hospitalization

         11. An active opportunistic disease not under adequate control in the opinion of the
             investigator

         12. Pregnant or nursing mothers

         13. Patients with current alcohol or illicit substance use that in the opinion of the
             investigator might adversely affect participation in the study

         14. Patients deemed unlikely by the investigator to be able to remain in follow-up for the
             protocol-defined period
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Polizzotto, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kirby Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Simone S Jacoby</last_name>
    <phone>+61 2 9385 0900</phone>
    <phone_ext>50919</phone_ext>
    <email>sjacoby@kirby.unsw.edu.au</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital G de Agudos JM Ramos Mejia</name>
      <address>
        <city>Buenos Aires</city>
        <state>Ciudad De Buenos Aires</state>
        <zip>C1221ADC</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marcelo Losso</last_name>
      <phone>5411 4127 0276</phone>
      <email>mlosso@hivramos.org.ar</email>
    </contact>
    <contact_backup>
      <last_name>Guillermo Viloria</last_name>
      <phone>5411 4931 5252</phone>
      <email>gviloria@hivramos.org.ar</email>
    </contact_backup>
    <investigator>
      <last_name>Marcelo Losso, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Dr Diego Paroissien</name>
      <address>
        <city>Isidro Casanova</city>
        <state>Provincia De Buenos Aires</state>
        <zip>1765</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eduardo Warley</last_name>
      <phone>5411 1541 897 181</phone>
      <email>eduwarley@yahoo.com.ar</email>
    </contact>
    <contact_backup>
      <last_name>Maria Ines Vieni</last_name>
      <phone>5411 1136 877 377</phone>
      <phone_ext>3340</phone_ext>
      <email>inesvieni@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Eduardo Warley, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CAICI</name>
      <address>
        <city>Rosario</city>
        <state>Provincia De Santa Fe</state>
        <zip>S2000PBJ</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sergio Lupo</last_name>
      <phone>54 9 341 515 7704</phone>
      <email>drsergiolupo@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Luciana Peroni</last_name>
      <phone>54 341 424 8045</phone>
      <email>administracioncaici@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Sergio Lupo, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Interzonal de Agudos San Juan de Dios</name>
      <address>
        <city>La Plata</city>
        <zip>1900</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martha Michaan</last_name>
      <phone>+54 9221 5765 131</phone>
      <email>mgmichaan@yahoo.com.ar</email>
    </contact>
    <investigator>
      <last_name>Martha Michaan, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Laboratório de Pesquisa Clinica Em Hiv/Aids - Instituto Nacional de Infectologia - Fiocruz</name>
      <address>
        <city>Rio de Janeiro</city>
        <zip>21040-360</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Beatriz Grinsztejn</last_name>
      <phone>+552122707064</phone>
      <email>beatriz.grinsztejn@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Kelly Gama</last_name>
      <phone>+552138659614</phone>
      <email>kelly.gama@ini.fiocruz.br</email>
    </contact_backup>
    <investigator>
      <last_name>Beatriz Grinsztejn, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital San Borja-Arriaran</name>
      <address>
        <city>Santiago</city>
        <zip>8360159</zip>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marcelo Wolff</last_name>
      <phone>562- 555 6206</phone>
      <email>marcewolff@yahoo.com</email>
    </contact>
    <contact_backup>
      <last_name>Gladys Allendes</last_name>
      <phone>562-555-6206</phone>
      <email>gladys_allendes@yahoo.es</email>
    </contact_backup>
    <investigator>
      <last_name>Marcelo Wolff, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ASISTENCIA Cientifica De Alta Complejidad S.A.S.</name>
      <address>
        <city>Bogota</city>
        <zip>110010</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Otto Sussmann</last_name>
      <phone>57-1- 5107600</phone>
      <phone_ext>104</phone_ext>
      <email>osussmann@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Ana Julia Rojas</last_name>
      <phone>57-1-5107600</phone>
      <phone_ext>128</phone_ext>
      <email>coord.investigaciones@asistenciacientifica.com</email>
    </contact_backup>
    <investigator>
      <last_name>Otto Sussmann, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre de traitementambulatoire de Donka ( Hopital de jour)</name>
      <address>
        <city>Conakry</city>
        <zip>BP:5845</zip>
        <country>Guinea</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mohamed Cisse</last_name>
      <phone>+224 622 292 590</phone>
      <email>cissebibi1@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Thierno Mamadou Tounkara</last_name>
      <phone>+224 622 318 171</phone>
      <email>tounkm@yahoo.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Mohamed Cisse, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CART CRS, VHS Hospital</name>
      <address>
        <city>Chennai</city>
        <state>Tamil Nadu</state>
        <zip>600113</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nagalingeswaran Kumarasamy</last_name>
      <phone>91 917 691 2007</phone>
      <email>kumarasamy@yrgcare.org</email>
    </contact>
    <contact_backup>
      <last_name>Faith Beulah</last_name>
      <phone>91 44 39106811</phone>
      <email>beulah@yrgcare.org</email>
    </contact_backup>
    <investigator>
      <last_name>Selvamuthu Poongulali, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dr. Cipto Mangunkusumo Hospital</name>
      <address>
        <city>Jakarta</city>
        <zip>10320</zip>
        <country>Indonesia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Evy Yunihastuti</last_name>
      <phone>+62811996058</phone>
      <email>evy.yunihastuti@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Bramantya Wicaksana</last_name>
      <phone>+6281384200298</phone>
      <email>bram1312@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Evy Yunihastuti, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>RSUP Dr. Wahidin Sudirohusodo</name>
      <address>
        <city>Makassar</city>
        <zip>90241</zip>
        <country>Indonesia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sudirman Katu</last_name>
      <phone>+6281342373900</phone>
      <email>sudirmankatu@yahoo.com</email>
    </contact>
    <contact_backup>
      <last_name>Yusran Ady Fitrah</last_name>
      <phone>+6281291819783</phone>
      <email>yusranadyfitrah7@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Sudirman Katu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dr. Soetomo Hospital</name>
      <address>
        <city>Surabaya</city>
        <zip>60285</zip>
        <country>Indonesia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Usman Hadi</last_name>
      <phone>+62818303105</phone>
      <email>usmanhadi@sby.centrin.net.id</email>
    </contact>
    <contact_backup>
      <last_name>Yufi Aulia Azmi</last_name>
      <phone>+6281330440545</phone>
      <email>yufiazmi@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Usman Hadi, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dr Sardjito Hospital</name>
      <address>
        <city>Yogyakarta</city>
        <zip>55284</zip>
        <country>Indonesia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yanri W Subronto</last_name>
      <phone>+62811255030</phone>
      <email>yanrisubronto@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Yusrina Adani</last_name>
      <phone>+6281328198127</phone>
      <email>yusrina.adani@yahoo.com</email>
    </contact_backup>
    <investigator>
      <last_name>Yanri Subronto, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Pulau Pinang</name>
      <address>
        <city>George Town</city>
        <state>Pulau Pinang</state>
        <zip>10450</zip>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ting Soo Chow, MD</last_name>
      <phone>+6042225712</phone>
      <email>drchowts@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Farhana N Abd Ghani</last_name>
      <phone>+6019-5004710</phone>
      <email>farhana.nadiah@clinicalresearch.my</email>
    </contact_backup>
    <investigator>
      <last_name>Ting Soo Chow, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Malaya Medical Centre</name>
      <address>
        <city>Kuala Lumpur</city>
        <zip>59100</zip>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Raja Iskandar Shah Raja Azwa</last_name>
      <phone>603-79493834</phone>
      <email>iskandar.azwa@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Margaret Tan</last_name>
      <phone>603-79492622</phone>
      <email>margarettan455@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Raja Iskandar Shah Raja Azwa, MBChB, MRCP</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Sciences, Techniques and Technologies of Mali, University Clinical Research Center (UCRC)</name>
      <address>
        <city>Bamako</city>
        <country>Mali</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sounkalo Doa</last_name>
      <phone>+223 72274971</phone>
      <email>sounkalod@icermali.org</email>
    </contact>
    <contact_backup>
      <last_name>Yacouba Cissoko</last_name>
      <phone>+22374567649 or +22397195994</phone>
      <email>ycissoko@hotmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Sounkalo Doa, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Morales Vargas Centro de Investigacion SC</name>
      <address>
        <city>León</city>
        <state>Guanajuato</state>
        <zip>37000</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juan Luis Mosqueda Gomez</last_name>
      <phone>+52 (477) 1310037</phone>
      <email>luis_mosqueda@yahoo.com</email>
    </contact>
    <contact_backup>
      <last_name>Jorge Morales Vargas</last_name>
      <phone>+52 (477) 7160714</phone>
      <email>mnc.jorge@hotmail.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Hospital Civil de Guadalajara</name>
      <address>
        <city>Guadalajara</city>
        <state>Jalisco</state>
        <zip>44280</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jaime Andrade-Villanueva</last_name>
      <email>jandradev@msn.com</email>
    </contact>
    <contact_backup>
      <last_name>Angeles González-Hernández</last_name>
      <phone>5233 3614 7586</phone>
      <email>angelesghdez1@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Jaime Andrade-Villanueva, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Instituto Nacional de Ciencias Medicas y Nutriciòn Salvador Zubiran</name>
      <address>
        <city>Mexico City</city>
        <zip>14080</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juan Sierra Madero</last_name>
      <phone>52 5556559675</phone>
      <email>jsmadero@yahoo.com</email>
    </contact>
    <contact_backup>
      <last_name>Izchel Loyo</last_name>
      <email>iz.inncm@outlook.com</email>
    </contact_backup>
    <investigator>
      <last_name>Juan Sierra Madero, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institute of Human Virology, Nigeria (IHVN)</name>
      <address>
        <city>Abuja</city>
        <zip>9396</zip>
        <country>Nigeria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nnakelu Eriobu</last_name>
      <phone>+2347039469273</phone>
      <email>neriobu@ihvnigeria.org</email>
    </contact>
    <contact_backup>
      <last_name>Maryam Almujtaba</last_name>
      <phone>+2347039469273</phone>
      <email>malmujtaba@ihvnigeria.org</email>
    </contact_backup>
    <investigator>
      <last_name>Nnakelu Eriobu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Desmond Tutu HIV Foundation</name>
      <address>
        <city>Cape Town</city>
        <zip>7925</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard Kaplan</last_name>
      <email>Richard.Kaplan@hiv-research.org.za</email>
    </contact>
    <contact_backup>
      <last_name>Christie Heiberg</last_name>
      <phone>27 21 406 3621</phone>
      <email>Christie.Heiberg@hiv-research.org.za</email>
    </contact_backup>
    <investigator>
      <last_name>Richard Kaplan, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinical HIV Research Unit (CHRU), Wits Health Consotium (Pty) Ltd</name>
      <address>
        <city>Johannesburg</city>
        <zip>2041</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Noluthando Mwelase</last_name>
      <email>tmwelase@witshealth.co.za</email>
    </contact>
    <contact_backup>
      <last_name>Pauline Vunandala</last_name>
      <phone>27 11 276 8800</phone>
      <email>pvunandlala@witshealth.co.za</email>
    </contact_backup>
    <investigator>
      <last_name>Noluthando Mwelase, MBCHB</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Perinatal HIV Research Unit (PHRU), Chris Hani Baragwanath Hospital</name>
      <address>
        <city>Soweto</city>
        <zip>1864</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lerato Mohapi</last_name>
      <email>mohapil@hivsa.com</email>
    </contact>
    <contact_backup>
      <last_name>Debra Peters</last_name>
      <phone>27 11 989 9700</phone>
      <email>petersd@phru.co.za</email>
    </contact_backup>
    <investigator>
      <last_name>Lerato Mohapi, BSc, MBBCh</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>HIV-NAT (The HIV Netherlands Australia Thailand Research Collaboration), Thai Red Cross AIDS Research Centre</name>
      <address>
        <city>Bangkok</city>
        <zip>10330</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anchalee Avihingsanon</last_name>
      <phone>+662 652 3040</phone>
      <phone_ext>107</phone_ext>
      <email>anchaleea2009@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Kanitta Pussadee</last_name>
      <phone>+662 652 3040</phone>
      <phone_ext>202</phone_ext>
      <email>kanitta.p@hivnat.org</email>
    </contact_backup>
    <investigator>
      <last_name>Anchalee Avihingsanon, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chiangrai Prachanukroh Hospital</name>
      <address>
        <city>Chiang Rai</city>
        <zip>57000</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Suwimon Khusuwan</last_name>
      <phone>66818859195</phone>
      <email>pachareek@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Supawadee Pongprapass</last_name>
      <phone>66819616900</phone>
      <email>npudit@hotmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Suwimon Khusuwan, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Srinagarind Hospital, Khon Kaen University</name>
      <address>
        <city>Khon Kaen</city>
        <zip>40002</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ploenchan Chetchotisakd</last_name>
      <phone>6643363168</phone>
      <email>ploencha@kku.ac.th</email>
    </contact>
    <contact_backup>
      <last_name>Anchalee Tiyabut</last_name>
      <phone>6643363169</phone>
      <email>atiyabut@yahoo.com</email>
    </contact_backup>
    <investigator>
      <last_name>Ploenchan Chetchotisakd, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bamrasnaradura Infectious Diseases Institute</name>
      <address>
        <city>Nonthaburi</city>
        <zip>11000</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Weerawat Manosuthi</last_name>
      <email>drweerawat@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Supeda Thongyen</last_name>
      <phone>6625903631</phone>
      <email>supeda_t@yahoo.com</email>
    </contact_backup>
    <investigator>
      <last_name>Weerawat Manosuthi, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Zimbabwe Clinical Research Centre</name>
      <address>
        <city>Harare</city>
        <zip>+263</zip>
        <country>Zimbabwe</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James G Hakim</last_name>
      <phone>263 772225489</phone>
      <email>Jhakim@mweb.co.zw</email>
    </contact>
    <contact_backup>
      <last_name>Shepherd Mudzingwa</last_name>
      <phone>263 4 701717</phone>
      <email>smudzingwa@yahoo.com</email>
    </contact_backup>
    <investigator>
      <last_name>James G Hakim, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Brazil</country>
    <country>Chile</country>
    <country>Colombia</country>
    <country>Guinea</country>
    <country>India</country>
    <country>Indonesia</country>
    <country>Malaysia</country>
    <country>Mali</country>
    <country>Mexico</country>
    <country>Nigeria</country>
    <country>South Africa</country>
    <country>Thailand</country>
    <country>Zimbabwe</country>
  </location_countries>
  <removed_countries>
    <country>Peru</country>
  </removed_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>January 2, 2017</study_first_submitted>
  <study_first_submitted_qc>January 9, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 11, 2017</study_first_posted>
  <last_update_submitted>February 2, 2020</last_update_submitted>
  <last_update_submitted_qc>February 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV, second-line</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Darunavir</mesh_term>
    <mesh_term>Dolutegravir</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

